Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment

S, Flanagan and A, Umaipalan and G, Baily and C, Orkin (2015) Sustained virological response after only 5 weeks treatment with daclatasvir/pegylated interferon and ribavirin as part of a clinical trial in a cirrhotic human immunodeficiency virus (HIV) - hepatitis C virus (HCV) co-infected patient with liver decompensation during treatment. Journal of AIDS and HIV Research, 7 (3). pp. 33-35. ISSN 2141-2359

Text
8E760E252083 - Published Version
Download (44kB)

Official URL: https://doi.org/10.5897/JAHR2015.0329

Abstract

This study presents a case of a sustained virological response to 24 weeks early cessation of hepatitis C direct acting antiviral (DAA) treatment with daclatasvir/peginterferon (PEG-IFN)/ribavirin (RBV), mandated by liver decompensation, in a clinical trial subject with advanced liver disease and human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection.

Item Type:	Article
Subjects:	AP Academic Press > Medical Science
Depositing User:	Unnamed user with email support@apacademicpress.com
Date Deposited:	16 Mar 2023 10:45
Last Modified:	19 Sep 2024 09:10
URI:	http://info.openarchivespress.com/id/eprint/765

Actions (login required)

: View Item